Vaccines Today—June 12, 2026

This weekly update in Vaccines and Immunization highlights key developments across vaccine research and clinical development, including early- and late-stage clinical progress, trial initiations, novel platform technologies, funding initiatives, and global research collaborations.

In Today’s Newsletter

Dive deeper

💉 AI-Designed Universal Coronavirus Vaccine Reports First Human Data [1] [11 Jun 2026]

https://www.cam.ac.uk/research/news/new-universal-vaccine-technology-could-protect-us-from-future-virus-outbreaks
Context: University of Cambridge and DIOSynVax tested a universal Sarbeco coronavirus vaccine in 39 healthy volunteers.
Key point: The vaccine was reported as safe and generated immune responses against SARS-CoV-2, SARS, and related bat coronaviruses.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Moderna and Oxford Advance Lynch Syndrome Cancer Prevention Vaccine [2] [UK • 08 Jun 2026]

https://feeds.issuerdirect.com/news-release.html?newsid=8652502498876158&symbol=MRNA
Context: The INTERCEPT-Lynch Phase 1/2 study will evaluate investigational mRNA-4194 in people with Lynch syndrome.
Key point: The UK MHRA authorized the study, which will assess safety, immune responses, and dose selection.
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 Soligenix Pursues CEPI Support for Bundibugyo Ebola Vaccine [3] [US • 08 Jun 2026]

https://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html
Context: Soligenix and collaborators previously developed thermostable filovirus vaccine candidates and generated preclinical data.
Key point: The company plans to submit a CEPI funding application to support rapid development of a Bundibugyo Ebola vaccine.
Implication: Signals pipeline investment and modality expansion.

👶 SK bioscience Licenses CDC Rotavirus Vaccine Technology [4]

https://www.skbioscience.com/en/news/news_01_01?mode=view&id=356
Context: The injectable inactivated rotavirus vaccine technology was originally developed by the U.S. CDC and previously entered Phase 1 testing.
Key point: SK bioscience began process development and plans further clinical development and commercialization.
Implication: May expand screening, initiation, and follow-up at scale.

🛡️ Invivyd Starts Phase 3 LIBERTY Trial for VYD2311 [5] [US • 09 Jun 2026]

https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-first-participants-dosed-liberty-phase-3
Context: LIBERTY is a randomized Phase 3 study comparing VYD2311, an mRNA COVID-19 vaccine, and co-administration in healthy adults.
Key point: First participants have been dosed; topline data are expected in Q3 2026 according to the company.
Implication: May influence prescriber choice and payer reviews pending full data.

🌍 Dual Lassa Fever and Rabies Vaccine Shows Early Clinical Promise [6] [US • 09 Jun 2026]

https://www.jefferson.edu/news/2026/06/nih-funded-researchers-share-early-results-lassa-fever-vaccine-clinical-trial.html
Context: The Phase 1 study evaluated LASSARAB, a rabies-vectored vaccine targeting both Lassa fever and rabies.
Key point: Interim results indicated the vaccine was well tolerated and generated immune responses against both targets.
Implication: May influence prescriber choice and payer reviews pending full data.

🌐 Rwanda Launches Multinational Chikungunya Vaccine Consortium [7] [Rwanda • 08 Jun 2026]

https://streamlinefeed.co.ke/news/rwanda-launches-15-million-chikungunya-vaccine-clinical-trial-consortium
Context: The ACT-CHIK initiative is funded through Horizon Europe and involves sites in Rwanda, Kenya, Nigeria, and Senegal.
Key point: The consortium will conduct Phase Ib and Phase III clinical studies of a measles-virus platform Chikungunya vaccine candidate.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Multiple programs are targeting broad protection against future outbreaks, including universal coronavirus and filovirus vaccine approaches.
Cancer prevention vaccines are moving beyond infectious disease applications, highlighted by Moderna’s Lynch syndrome program.
Thermostable and injectable vaccine platforms could improve deployment in low-resource settings.
African-led clinical trial infrastructure continues to expand through multinational programs such as ACT-CHIK.
Several programs advanced into new clinical stages this week, from Phase 1 readouts to Phase 3 enrollment.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Vaccine news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is the significance of the Cambridge and DIOSynVax universal coronavirus vaccine?

The vaccine uses an AI-designed antigen intended to provide broad protection across Sarbeco coronaviruses. Early human data reported safety and immune responses against multiple related viruses. [1]

What is Moderna’s mRNA-4194 program for Lynch syndrome?

mRNA-4194 is an investigational cancer prevention vaccine designed to generate immune responses against targets associated with early cancer development in people with Lynch syndrome. [2]

What makes the Soligenix Bundibugyo Ebola effort different?

The program builds on a thermostable protein-subunit vaccine platform intended to simplify storage and distribution while supporting rapid outbreak response. [3]

Why is SK bioscience’s rotavirus project notable?

The company licensed injectable rotavirus vaccine technology from the CDC and aims to advance a candidate that could address limitations associated with oral vaccination in some regions. [4]

What is being studied in Invivyd’s LIBERTY trial?

LIBERTY is evaluating the safety, tolerability, and immunology of VYD2311 alone, mRNA COVID-19 vaccination alone, and co-administration. [5]

What did the LASSARAB Phase 1 study show?

Researchers reported that the vaccine was well tolerated and generated immune responses against both Lassa fever and rabies in healthy adults. Efficacy was not assessed in this early-stage study. [6]

Entities / Keywords

University of Cambridge, DIOSynVax (DVX), universal vaccine, Sarbeco coronavirus
Moderna, University of Oxford, mRNA-4194, INTERCEPT-Lynch, Lynch syndrome
Soligenix, ThermoVax, CEPI, Bundibugyo virus, Ebola
SK bioscience, CDC, rotavirus vaccine, RIGHT Foundation
Invivyd, VYD2311, LIBERTY, REVOLUTION, COVID-19 monoclonal antibody
Thomas Jefferson University, University of Maryland, LASSARAB, Lassa fever, rabies
ACT-CHIK, University of Rwanda, Chikungunya, Horizon Europe, FIOCRUZ, International Vaccine Institute